

## EXTRAORDINARY GENERAL MEETING

### TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)

(Company Registration No.91120000103100784F)

(Incorporated in the People's Republic of China)

(the "**Company**")

### NOTICE OF EXTRAORDINARY GENERAL MEETING

#### IMPORTANT NOTE FOR S-SHARE SHAREHOLDERS:

This Notice of Extraordinary General Meeting has been given in compliance with Article 69 of the Articles of Association of the Company and the listing rules of the Shanghai Stock Exchange which require the Company to issue a written notice 45 days in advance of a shareholders' meeting.

The Company will issue a revised Notice of Extraordinary General Meeting 14 days before the Extraordinary General Meeting in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, to provide the S-Share Shareholders with the details in relation to the arrangements for participation at the Extraordinary General Meeting by S-Share Shareholders in Singapore. S-Share Shareholders should check the SGXNET for the latest updates on the status of the Extraordinary General Meeting.

**NOTICE IS HEREBY GIVEN** that an extraordinary general meeting ("**EGM**" or "**Extraordinary General Meeting**") of the Company will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the People's Republic of China (the "**PRC**") 300193 on Tuesday, 28 November 2023 at 2:00 p.m.. Concurrently, a video conferencing at The Pavillion, KLOUD Keppel Bay Tower, 1 HarbourFront Avenue, Level 13 Keppel Bay Tower, Singapore 098632 for holders of S-Shares ("**S-Share Shareholders**") in Singapore.

To consider and, if thought fit, approve the following resolutions, with or without modifications:

#### RESOLUTION(S) (POLL VOTING)

**Resolution 1:** To consider and approve the proposed appointment of CAC Certified Public Accountants LLP (中审华会计师事务所) as the PRC auditors of the Company for the financial year ending 31 December 2023 ("**FY2023**") to hold office until the conclusion of the next annual general meeting, and the proposed appointment of Foo Kon Tan Grant Thornton LLP as international auditors of the Company for FY2023 to hold office until the conclusion of the next annual general meeting, and to propose for the shareholders of the Company ("**Shareholders**") at the Extraordinary General Meeting to authorise the Board to determine their respective remuneration;

#### RESOLUTION(S) (CUMULATIVE VOTING)

**Resolution 2.1:** To consider and approve the proposed re-appointment of Mr. Liew Yoke Pheng Joseph (刘育彬) as an independent director of the Company with effect from the date of the Extraordinary General Meeting; and

**Resolution 2.2:** To consider and approve the proposed appointment of Mr. Yeo Guat Kwang (杨木光) as an independent director of the Company with effect from the date of the Extraordinary General Meeting.

### By Order of the Board

Jiao Yan  
Secretary to the Board of Directors  
13 October 2023

### Notes:

1. Resolution 1 has been approved by the Board at a Board meeting of the Company held on 14 August 2023, and Resolutions 2.1 and 2.2 have been approved by the Board at a Board meeting of the Company held on 13 October 2023.
2. The EGM will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, a video conferencing at The Pavillion, KLOUD Keppel Bay Tower, 1 HarbourFront Avenue, Level 13 Keppel Bay Tower, Singapore 098632 for S-Share Shareholders in Singapore) on Tuesday, 28 November 2023 at 2:00 p.m..

As disclosed above, the Company will issue a revised Notice of EGM 14 days before the EGM in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, to provide the S-Share Shareholders with the details in relation to the arrangements for participation at the EGM by S-Share Shareholders in Singapore including detailed instructions to S-Share Shareholders on how they may cast their votes with respect to Resolutions 2.1 and 2.2 by way of cumulative voting. S-Share Shareholders should check the SGXNET for the latest updates on the status of the EGM.

3. A Shareholder (whether individual or corporate) entitled to attend and vote at the EGM is entitled to appoint one (1) or more persons (who need not also be a Shareholder) to act as his/ her/ its proxy(ies) to attend and vote on his /her/ its behalf at the EGM. Where a Shareholder appoints more than one (1) proxy, the appointment shall be deemed to be as an alternative unless he/ she/ it specifies the proportion of his/ her/ its shareholding (expressed as a percentage of the whole) to be represented by each proxy.

If the appointor is a corporation, the proxy must be executed under seal or the hand of its duly authorised officer or attorney.

4. Pursuant to the Articles of Association of the Company, a holder of tradable domestic A-Shares with limiting conditions for sale shall notify the Company in writing not less than 20 days prior to the EGM of his or her intention to attend the EGM. Accordingly, a holder of tradable domestic A-Shares with limiting conditions for sale who is planning to attend the EGM must give a written notice to the Company no later than 2 November 2023.
5. The EGM in Tianjin, PRC is expected to last for half a day and all accommodation and other expenses incurred by a Shareholder or his/ her/ its proxy(ies) in connection with his/ her/ its attendance at the EGM shall be borne by that Shareholder.
6. **Personal data privacy:** By (1) submitting a proxy form appointing a proxy(ies) and/ or representative(s) to attend, speak and vote at the EGM and/ or any adjournment thereof, (2) submitting any question prior to the EGM, a Shareholder of the Company (a) consents to the collection, use and disclosure of the Shareholder's personal data by the Company (or its agents or service providers) for the purposes of (i) the processing and administration by the Company (or its agents or service providers) of proxies and representatives appointed for the EGM (including any adjournment thereof), (ii) the preparation and compilation of the attendance lists, minutes and other documents relating to the EGM (including any adjournment thereof), (iii) the addressing of substantial and relevant questions relating to the resolutions to be tabled for approval at the EGM from Shareholders received prior to and/ or at the EGM and if necessary, the following up with Shareholders in relation to such questions, and (iv) in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/ or guidelines (collectively, the "**Purposes**"), (b) warrants that where a Shareholder discloses the personal data of such Shareholder's proxy(ies) and/ or representative(s) to the Company (or its agents or service providers), such

Shareholder has obtained the prior consent of such proxy(ies) and/ or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/ or representative(s) for the Purposes, and (c) agrees that the Shareholder will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the Shareholder's breach of warranty.